WPRIM Management System> DCMS> Journal of Clinical Hepatology> 2023> 39> 3

Volume: 39 Issue: 3

1. Liver pathology from the perspective of clinicians Page:489—490
2. Diagnosis of nonalcoholic fatty liver disease: The importance of pathology Page:491—497
3. Thinking of the pathological diagnosis of unexplained liver cirrhosis Page:498—503
4. Diagnosis and treatment of autoimmune hepatitis: The indispensable role of pathology Page:504—510
5. Diagnosis and treatment of primary biliary cholangitis: Is pathology necessary? Page:511—516
6. Differential pathological diagnosis of liver tissue with normal appearance Page:517—522
7. Can green tea extract cause specific liver injury?——Discussion of the latest US guidelines on drug-induced liver injury Page:523—526
8. Guidelines on the management of esophagogastric variceal bleeding in cirrhotic portal hypertension Page:527—538
9. Efficacy and safety of the 12-week sofosbuvir-coblopasvir regimen in treatment of chronic hepatitis C Page:539—545
10. Value of triglyceride-glucose index combined with obesity index in predicting nonalcoholic fatty liver disease in individuals with obstructive sleep apnea Page:546—551
11. Association between the rs1800591 variation of the microsomal triglyceride transfer protein gene and the risk of nonalcoholic fatty liver disease in the elderly population Page:552—561
12. Changes in the frequency, phenotype, and function of mucosal-associated invariant T lymphocytes in peripheral blood of children with metabolic associated fatty liver disease Page:562—566
13. Association between primary sclerosing cholangitis and the risk of colorectal cancer: A two-sample Mendelian randomization study Page:567—572
14. Value of liver-muscle signal intensity and serum markers in diagnosis of chronic hepatitis B liver fibrosis Page:573—579
15. Association of P-I-R classification and Laennec grading with histology and prognosis after antiviral therapy in patients with hepatitis B cirrhosis Page:580—589
16. Value of different scoring models in predicting the survival of patients with liver cirrhosis after transjugular intrahepatic portosystemic shunt Page:590—598
17. Value of a scoring system based on the serum levels of alpha-fetoprotein and alkaline phosphatase in predicting the prognosis of patients with resectable hepatocellular carcinoma Page:599—605
18. Value of total bilirubin rebound rate and total bilirubin clearance rate in evaluating the prognosis of severe drug-induced liver injury after artificial liver support therapy Page:606—612
19. Value of a risk assessment model in predicting venous thromboembolism in patients with liver failure after artificial liver support therapy Page:613—619
20. Clinical features of patients with portal hypertension due to Abernethy malformation: An analysis of 5 cases Page:620—625
21. Transient aplastic anemia associated with acute hepatitis B: A case report Page:626—629
22. A case of Danon's disease with recurrent abnormal liver function Page:630—633
23. Streptococcus constellatus liver abscess caused by fish bone: A case report Page:634—636
24. Endoscopic sequential ligation for treatment of esophageal and gastric varices with duodenal varices: A case report Page:637—639
25. Massive hepatic hemangioma with diffuse arterioportal fistula: A case report Page:640—643
26. Role of new serological markers in evaluating the progression of liver disease in patients with chronic HBV infection and normal aminotransferases Page:644—650
27. Research advances in hepatitis B virus-associated glomerulonephritis Page:651—656
28. Role of serum Golgi protein 73 in nonalcoholic fatty liver disease Page:657—662
29. Research advances in effective constituents of traditional Chinese medicine in intervention of autoimmune hepatitis-related signaling pathways Page:663—670
30. Research advances in the association between sarcopenia and hepatic encephalopathy in patients with liver cirrhosis Page:671—676
31. Application of near-infrared fluorescence imaging in hepatectomy of hepatocellular carcinoma Page:677—683
32. Current reviewers Page:683—683
33. Influence of the interaction between tumor microenvironment and liver cancer stem cells on the development and progression of hepatocellular carcinoma Page:684—692
34. Association of folic acid with the development and progression of liver cancer Page:693—698
35. Role of stem cell-derived exosomes in treatment of liver diseases Page:699—706
36. Role of gasdermin D in the pathological progression of liver diseases Page:707—712
37. Trends in nano-antimicrobial therapy for severe liver disease with infection Page:713—717
38. Role of A-kinase anchor protein 12 in chronic liver diseases Page:718—722
39. Advances in the treatment of iatrogenic bile duct injury Page:723—728

©2019 - Present World Health Organization Regional Office for the Western Pacific. All Rights Reserved.